文献速递复苏、休克与脓毒症心脑血管急症

肾上腺素用于院外心脏骤停:更新的系统评价与Meta分析

Epinephrine for Out-of-Hospital Cardiac Arrest: An Updated Systematic Review and Meta-Analysis.
PubMed 文献 · Crit Care Med · 2020-01-01
一句话结论与安慰剂相比,标准剂量肾上腺素改善院外心脏骤停患者总体生存但未改善神经功能结局,主要基于一项随机对照试验。

该系统评价与Meta分析纳入17项随机及准随机对照试验共21510例患者,比较标准剂量肾上腺素与安慰剂、高或低剂量肾上腺素、其他血管加压药单用或联用。与安慰剂相比,两项试验合并结果显示标准剂量肾上腺素提高自主循环恢复(RR 3.09,95%CI 2.82-3.89)、入院生存(RR 2.50,95%CI 1.68-3.72)和出院生存(RR 1.44,95%CI 1.11-1.86);最大安慰剂对照试验显示其改善30天和3个月生存但不改善神经功能结局。与高剂量肾上腺素相比,标准剂量降低自主循环恢复(RR 0.87,95%CI 0.77-0.98)和入院生存(RR 0.88,95%CI 0.78-0.99)。标准剂量肾上腺素与血管加压素单用或联用的结局无差异。

要点

  • 与安慰剂相比,标准剂量肾上腺素提高院外心脏骤停患者出院生存(RR 1.44,95%CI 1.11-1.86),但不改善神经功能结局。
  • 与高剂量肾上腺素相比,标准剂量降低自主循环恢复(RR 0.87,95%CI 0.77-0.98)和入院生存(RR 0.88,95%CI 0.78-0.99)。
  • 标准剂量肾上腺素与血管加压素单用或联用相比,结局无差异。
  • 最大安慰剂对照试验显示标准剂量肾上腺素改善30天和3个月生存,但未改善神经功能结局。
  • 17项试验共21510例患者,其中7项被判定为高偏倚风险。

适用人群与场景

  • 成人院外心脏骤停复苏患者。

研究设计与关键结果

  • 系统评价与Meta分析纳入17项随机及准随机对照试验共21510例患者,其中7项被判定为高偏倚风险。
  • 与安慰剂相比,两项试验合并结果显示标准剂量肾上腺素提高自主循环恢复(RR 3.09,95%CI 2.82-3.89)、入院生存(RR 2.50,95%CI 1.68-3.72)和出院生存(RR 1.44,95%CI 1.11-1.86)。
  • 最大安慰剂对照试验显示标准剂量肾上腺素改善30天和3个月生存,但不改善神经功能结局。
  • 与高剂量肾上腺素相比,标准剂量肾上腺素降低自主循环恢复(RR 0.87,95%CI 0.77-0.98)和入院生存(RR 0.88,95%CI 0.78-0.99)。
  • 标准剂量肾上腺素与血管加压素单用或联用相比,结局无差异。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入随机及准随机对照试验。
  • 局限性:17项试验中7项被判定为高偏倚风险;作者指出缺乏具有重要患者结局的试验,未来肾上腺素试验应评估剂量和给药方法对长期生存、神经功能及心脏骤停后生活质量的影响。

对床旁实践的改变

  • 作者认为,与安慰剂相比,标准剂量肾上腺素改善院外心脏骤停患者总体生存但不改善神经功能结局,该结论主要基于一项随机对照试验。
  • 作者建议,未来肾上腺素试验应评估剂量和给药方法对长期生存、神经功能及心脏骤停后生活质量的影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To perform an updated systematic review and meta-analysis of clinical trials evaluating epinephrine for adult out-of-hospital cardiac arrest resuscitation.

DATA SOURCES: The search included MEDLINE, EMBASE, and Ovid Evidence-Based Medicine, clinical trial registries, and bibliographies.

STUDY SELECTION: Randomized and quasi-randomized controlled trials that compared the current standard dose of epinephrine to placebo, high or low dose epinephrine, any other vasopressor alone or in combination were screened by three independent reviewers.

DATA EXTRACTION: Randomized and quasi-randomized controlled trials that compared the current standard dose of epinephrine to placebo, high or low dose epinephrine, any other vasopressor alone or in combination were screened by three independent reviewers.

DATA SYNTHESIS: A total of 17 trials (21,510 patients) were included; seven were judged to be at high risk of bias. Compared to placebo, pooled results from two trials showed that standard dose of epinephrine increased return of spontaneous circulation (risk ratio, 3.09; 95% CI, 2.82-3.89), survival to hospital admission (risk ratio, 2.50; 95% CI, 1.68-3.72), and survival to discharge (risk ratio, 1.44; 95% CI, 1.11-1.86). The largest placebo-controlled trial showed that standard dose of epinephrine also improved survival at 30 days and 3 months but not neurologic outcomes, standard dose of epinephrine decreased return of spontaneous circulation (risk ratio, 0.87; 95% CI, 0.77-0.98) and survival to admission (risk ratio, 0.88; 95% CI, 0.78-0.99) when compared with high dose epinephrine. There were no differences in outcomes between standard dose of epinephrine and vasopressin alone or in combination with epinephrine.

CONCLUSIONS: Largely based on one randomized controlled trial, standard dose of epinephrine improved overall survival but not neurologic outcomes in out-of-hospital cardiac arrest patients compared with placebo. There is a paucity of trials with meaningful patient outcomes; future epinephrine trials should evaluate dose and method of delivery on long-term survival, neurologic function, and quality of life after cardiac arrest.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Aves T, Chopra A, Patel M, et al. Epinephrine for Out-of-Hospital Cardiac Arrest: An Updated Systematic Review and Meta-Analysis. Crit Care Med. 2020. PMID: 31939791. doi:10.1097/CCM.0000000000004130

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。